ZURICH, Dec 29 (Reuters) - Novartis AG will license a programme of vaccines from U.S. group AlphaVax against cytomegalovirus (CMV) infections, which can cause disability in newborn babies, the Swiss drugmaker said on Monday.
ZURICH, Dec 29 (Reuters) - Novartis AG will license a programme of vaccines from U.S. group AlphaVax against cytomegalovirus (CMV) infections, which can cause disability in newborn babies, the Swiss drugmaker said on Monday.
